What is the share price of Eris Lifesciences Ltd (ERIS) today?
The share price of ERIS as on 20th August 2026 is ₹1336.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Eris Lifesciences Ltd (ERIS) share?
The past returns of Eris Lifesciences Ltd (ERIS) share are- Past 1 week: -2.65%
- Past 1 month: -6.46%
- Past 3 months: 1.03%
- Past 6 months: 1.63%
- Past 1 year: -22.46%
- Past 3 years: 62.60%
- Past 5 years: 84.15%
What are the peers or stocks similar to Eris Lifesciences Ltd (ERIS)?
The peers or stocks similar to Eris Lifesciences Ltd (ERIS) include:What is the dividend yield % of Eris Lifesciences Ltd (ERIS) share?
The current dividend yield of Eris Lifesciences Ltd (ERIS) is 0.51.What is the market cap of Eris Lifesciences Ltd (ERIS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Eris Lifesciences Ltd (ERIS) is ₹19267.24 Cr as of 20th August 2026.What is the 52 week high and low of Eris Lifesciences Ltd (ERIS) share?
The 52-week high of Eris Lifesciences Ltd (ERIS) is ₹1818.80 and the 52-week low is ₹1200.What is the PE and PB ratio of Eris Lifesciences Ltd (ERIS) stock?
The P/E (price-to-earnings) ratio of Eris Lifesciences Ltd (ERIS) is 31.10. The P/B (price-to-book) ratio is 5.89.Which sector does Eris Lifesciences Ltd (ERIS) belong to?
Eris Lifesciences Ltd (ERIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Eris Lifesciences Ltd (ERIS) shares?
You can directly buy Eris Lifesciences Ltd (ERIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Eris Lifesciences Ltd
ERIS Share Price
NSE₹1,336.900.97% (-13.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ERIS Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ERIS Performance & Key Metrics
ERIS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.92 | 5.89 | 0.51% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.98 | 6.02 | 0.49% |
90%
Analysts have suggested that investors can buy this stock
from 10 analysts
Price Upside
Earnings Growth
Rev. Growth
ERIS Company Profile
Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market
SUNPHARMA
PE Ratio
40.59
40.59
1Y Return
16.74%
16.74%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
85.91
85.91
1Y Return
37.34%
37.34%
Buy Reco %
82.14
82.14
ZYDUSLIFE
PE Ratio
23.57
23.57
1Y Return
12.18%
12.18%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
30.47
30.47
1Y Return
8.19%
8.19%
Buy Reco %
62.86
62.86
LUPIN
PE Ratio
19.54
19.54
1Y Return
12.92%
12.92%
Buy Reco %
54.55
54.55
ERIS Sentiment Analysis
ERIS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ERIS Stock Summary · November 2025
In Q2, the company demonstrated robust growth, with a 10% increase in domestic branded formulations revenue, outpacing the pharmaceutical market. Despite facing challenges such as product approval delays and GST-related cash flow issues, it remains optimistic about future demand, particularly in the insulin and GLP-1 markets, which are projected to expand significantly. Strategic partnerships, including an enhanced collaboration with Biocon, and substantial capital investments in production capacity position the company favorably for upcoming market opportunities. Additionally, a focus on international expansion aims to diversify revenue streams, with expectations of transitioning to a more balanced portfolio that includes regulated launch drugs. Overall, the company is well-prepared to capitalize on evolving market dynamics while maintaining a conservative financial strategy.
ERIS Stock Growth Drivers
ERIS Stock Growth Drivers
8Strong Revenue Growth in Domestic Formulations
Eris Lifesciences has achieved a 10% year-over-year growth in domestic branded formulations revenue for Q2,
Expansion of Insulin Production Capacity
The company has successfully operationalized its vial production, producing approximately 2 million vials since going
ERIS Stock Challenges
ERIS Stock Challenges
2Lower Operating Cash Flow (OCF) Issues
The company is experiencing a significant decline in its operating cash flow (OCF) relative to
Future Challenges Related to GST
There are anticipated future challenges stemming from the ongoing GST-related disruptions. The company is facing
ERIS Forecast
ERIS Forecasts
Price
Revenue
Earnings
ERIS Share Price Forecast
ERIS Share Price Forecast
2026
Current
₹1,350.00
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,350.00
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ERIS Company Revenue Forecast
ERIS Company Revenue Forecast
2026
Current
₹3.14
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹3.14
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ERIS Stock EPS (Earnings Per Share) Forecast
ERIS Stock EPS (Earnings Per Share) Forecast
2026
Current
₹45.33
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹45.33
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ERIS
ERIS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ERIS Income Statement
ERIS Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 566.08 | 721.36 | 745.72 | 731.67 | 713.31 | 776.58 | 795.50 | 807.59 | 758.79 | 875.64 | ||||||||||
Operating & Other expenses | 402.50 | 469.73 | 476.66 | 477.14 | 452.91 | 496.29 | 504.20 | 543.08 | 484.19 | 577.43 | ||||||||||
EBITDA | 163.58 | 251.63 | 269.06 | 254.53 | 260.40 | 280.29 | 291.30 | 264.51 | 274.60 | 298.21 | ||||||||||
| Depreciation/Amortization | 53.80 | 75.74 | 80.48 | 81.00 | 77.25 | 70.51 | 69.08 | 70.34 | 69.57 | 72.07 | ||||||||||
| PBIT | 109.78 | 175.89 | 188.58 | 173.53 | 183.15 | 209.78 | 222.22 | 194.17 | 205.03 | 226.14 | ||||||||||
| Interest & Other Items | 33.03 | 60.37 | 59.47 | 57.17 | 54.28 | 48.68 | 49.55 | 48.82 | 45.62 | 46.65 | ||||||||||
| PBT | 76.75 | 115.52 | 129.11 | 116.36 | 128.87 | 161.10 | 172.67 | 145.35 | 159.41 | 179.49 | ||||||||||
| Taxes & Other Items | 5.72 | 32.21 | 37.52 | 32.60 | 35.03 | 43.11 | 52.48 | 45.63 | -122.20 | 37.10 | ||||||||||
| Net Income | 71.03 | 83.31 | 91.59 | 83.76 | 93.84 | 117.99 | 120.19 | 99.72 | 281.61 | 142.39 | ||||||||||
| EPS | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 | 8.66 | 8.82 | 7.32 | 20.60 | 10.28 |
ERIS Company Updates
FY 2027FY 2027
Investor Presentation
Jul 29PDF
FY 2026FY 2026
Investor Presentation
May 20PDF
Feb 13PDF
Nov 12PDF
Aug 5PDF
ERIS Stock Peers
ERIS Past Performance & Peer Comparison
ERIS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Eris Lifesciences Ltd | 31.10 | 5.89 | 0.51% |
| Sun Pharmaceutical Industries Ltd | 40.59 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 85.91 | 10.57 | 0.69% |
| Zydus Lifesciences Ltd | 23.57 | 4.02 | 0.08% |
ERIS Stock Price Comparison
Compare ERIS with any stock or ETFCompare ERIS with any stock or ETF
ERIS
ERIS Holdings
ERIS Shareholdings
ERIS Promoter Holdings Trend
ERIS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ERIS Institutional Holdings Trend
ERIS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ERIS Shareholding Pattern
ERIS Shareholding Pattern
ERIS Shareholding History
ERIS Shareholding History
Foreign Institutions
Mutual Funds Invested in ERIS
Mutual Funds Invested in ERIS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Eris Lifesciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.5453% | Percentage of the fund’s portfolio invested in the stock 2.10% | Change in the portfolio weight of the stock over the last 3 months -0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 46/87 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7294% | Percentage of the fund’s portfolio invested in the stock 1.48% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 41/145 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.5565% | Percentage of the fund’s portfolio invested in the stock 2.09% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 4/100 (+3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ERIS stock
smallcases containing ERIS stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd
ERIS Events
ERIS Events
ERIS Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ERIS Dividend Trend
No dividend trend available
ERIS Upcoming Dividends
ERIS Upcoming Dividends
No upcoming dividends are available
ERIS Past Dividends
ERIS Past Dividends
Cash Dividend
Ex DateEx DateMay 29, 2026
Interim
Interim | Div/Share: ₹7.21
Dividend/Share
₹7.21
Ex DateEx Date
May 29, 2026
Cash Dividend
Ex DateEx DateFeb 13, 2025
Interim
Interim | Div/Share: ₹7.35
Dividend/Share
₹7.35
Ex DateEx Date
Feb 13, 2025
Cash Dividend
Ex DateEx DateAug 11, 2022
Interim
Interim | Div/Share: ₹7.35
Dividend/Share
₹7.35
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Interim
Interim | Div/Share: ₹6.01
Dividend/Share
₹6.01
Ex DateEx Date
Aug 5, 2021
Cash Dividend
Ex DateEx DateAug 13, 2020
Interim
Interim | Div/Share: ₹5.50
Dividend/Share
₹5.50
Ex DateEx Date
Aug 13, 2020
ERIS Stock News & Opinions
ERIS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Eris Lifesciences allotted shares under its ESOP scheme, raising paid-up capitalEris Lifesciences Limited announced on July 30, 2026, the allotment of 4,816 equity shares at a premium of Rs 450.04 per share, pursuant to the exercise of options under the ESOP-2017 Scheme, increasing the company's paid-up share capital from Rs 13,85,78,489 to Rs 13,85,83,305.
2 weeks agoCapital Market - Live
Spotlight
Spotlight
Eris Lifesciences gains after Q1 PAT climbs 21% YoY to rs 142 crRevenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter. Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27. EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26. During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Earnings
ERIS Lifesciences consolidated net profit rises 20.68% in the June 2026 quarterNet profit of ERIS Lifesciences rose 20.68% to Rs 142.39 crore in the quarter ended June 2026 as against Rs 117.99 crore during the previous quarter ended June 2025. Sales rose 12.63% to Rs 869.03 crore in the quarter ended June 2026 as against Rs 771.56 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales869.03771.56 13 OPM %34.0435.86 - PBDT251.56231.61 9 PBT179.49161.10 11 NP142.39117.99 21 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Corporate
ERIS Lifesciences to table resultsERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2026.
3 weeks agoCapital Market - Live
Earnings
Earnings
ERIS Lifesciences consolidated net profit rises 200.10% in the March 2026 quarterNet profit of ERIS Lifesciences rose 200.10% to Rs 281.61 crore in the quarter ended March 2026 as against Rs 93.84 crore during the previous quarter ended March 2025. Sales rose 7.07% to Rs 752.29 crore in the quarter ended March 2026 as against Rs 702.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 76.08% to Rs 619.52 crore in the year ended March 2026 as against Rs 351.84 crore during the previous year ended March 2025. Sales rose 8.18% to Rs 3114.89 crore in the year ended March 2026 as against Rs 2879.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales752.29702.60 7 3114.892879.26 8 OPM %36.2135.92 -35.9635.33 - PBDT228.98206.12 11 935.28804.33 16 PBT159.41128.87 24 655.78488.87 34 NP281.6193.84 200 619.52351.84 76 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Board of ERIS Lifesciences recommends interim dividendERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 20 May 2026, inter alia, have recommended the interim dividend of Rs 7.21 per equity Share (i.e. 721%) , subject to the approval of the shareholders.
3 months agoCapital Market - Live
Spotlight
Spotlight
Eris Lifesciences spurts after Q4 PAT skyrockets 200% YoY to Rs 282 crTotal revenue from operations rose 7.26% to Rs 756.56 crore in Q4 FY26 over Q4 FY25. Profit before tax (PBT) stood at Rs 159.41 crore in Q4 FY26, up 23.69% from Rs 128.87 crore recorded in the same quarter last year. During the quarter EBITDA stood at Rs 274 crore, up 8% compared with Rs 252 crore posted in same quarter last year. EBITDA margin expanded to 36.2% in Q4 FY26 as against 35.8% in Q4 FY25. Revenue from domestic branded formulation (DBF) business jumped 12% YoY to Rs 671 crore in Q4 FY26. The International Business fell 8% to Rs 86 crore in Q4 FY26. The company declared an interim dividend of Rs 7.21 per fully paid-up equity share of Re 1 each (721%) for FY27. It has fixed Friday, May 29, 2026, as the record date to determine shareholders' eligibility for the interim dividend. The dividend will be paid on or before June 19, 2026. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
ERIS Lifesciences to hold board meetingERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 20 May 2026.
3 months agoCapital Market - Live
Corporate
Corporate
ERIS Lifesciences allots 24,396 equity shares under ESOPERIS Lifesciences has allotted 24,396 equity shares under ESOP on 11 May 2026. The paid-up share capital of the Company accordingly stands increased from Rs 13,85,42,887/- (13,85,42,887 equity shares of Re 1/- each) to Rs 13,85,67,256/- (13,85,67,256 equity shares of Re 1/- each).
3 months agoCapital Market - Live
Corporate
Corporate
Eris Lifesciences receives affirmation in credit ratingsEris Lifesciences has received affirmation in credit ratings for non convertible debentures and bank facilities at IND AA; Stable/ IND A1+ from India Ratings and Research. The company's issuer rating has been affirmed at IND AA; Stable.
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 20.78%, vs industry avg of 12.51%
Over the last 5 years, market share increased from 0.43% to 0.61%
Over the last 5 years, net income has grown at a yearly rate of 11.77%, vs industry avg of 10.55%